Avidity Biosciences, Inc. RNA
We take great care to ensure that the data presented and summarized in this overview for Avidity Biosciences, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding RNA
View all-
Janus Henderson Group PLC London, X011.4MShares$329 Million0.19% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD11.3MShares$327 Million0.04% of portfolio
-
Wellington Management Group LLP Boston, MA9.68MShares$279 Million0.06% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.24MShares$266 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY8.75MShares$252 Million4.23% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$248 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY7.63MShares$220 Million3.64% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.3MShares$181 Million3.86% of portfolio
-
State Street Corp Boston, MA4.32MShares$124 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA2.76MShares$79.4 Million0.01% of portfolio
Latest Institutional Activity in RNA
Top Purchases
Top Sells
About RNA
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
Insider Transactions at RNA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 17
2025
|
Kathleen P. Gallagher Chief Program Officer |
SELL
Open market or private sale
|
Direct |
911
-1.78%
|
$27,330
$30.24 P/Share
|
|
Jun 11
2025
|
W. Michael Flanagan Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
20,000
-19.96%
|
$640,000
$32.88 P/Share
|
|
Jun 11
2025
|
W. Michael Flanagan Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+16.64%
|
$280,000
$14.22 P/Share
|
|
Jun 10
2025
|
Carsten Boess Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,692
+50.0%
|
-
|
|
Jun 10
2025
|
Noreen Henig Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,692
+50.0%
|
-
|
|
Jun 10
2025
|
Arthur A Levin Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,692
+25.4%
|
-
|
|
Jun 10
2025
|
Edward M. Md Kaye Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,692
+50.0%
|
-
|
|
Jun 10
2025
|
Simona Skerjanec Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,692
+50.0%
|
-
|
|
Jun 10
2025
|
Troy Edward Wilson Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,692
+8.79%
|
-
|
|
Jun 10
2025
|
Jean Jinsun Kim Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,692
+50.0%
|
-
|
|
Jun 10
2025
|
Tamar Thompson Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,692
+50.0%
|
-
|
|
Jun 02
2025
|
Kathleen P. Gallagher Chief Program Officer |
SELL
Open market or private sale
|
Direct |
5,875
-10.41%
|
$188,000
$32.48 P/Share
|
|
Jun 02
2025
|
Kathleen P. Gallagher Chief Program Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,875
+9.43%
|
$94,000
$16.65 P/Share
|
|
May 01
2025
|
Kathleen P. Gallagher Chief Program Officer |
SELL
Open market or private sale
|
Direct |
5,875
-10.41%
|
$188,000
$32.4 P/Share
|
|
May 01
2025
|
Kathleen P. Gallagher Chief Program Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,875
+9.43%
|
$94,000
$16.65 P/Share
|
|
Apr 01
2025
|
Kathleen P. Gallagher Chief Program Officer |
SELL
Open market or private sale
|
Direct |
5,875
-5.27%
|
$158,625
$27.83 P/Share
|
|
Apr 01
2025
|
Kathleen P. Gallagher Chief Program Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,875
+4.82%
|
$88,125
$15.68 P/Share
|
|
Mar 20
2025
|
W. Michael Flanagan Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
11,780
-12.81%
|
$365,180
$31.06 P/Share
|
|
Mar 20
2025
|
Sarah Boyce President and CEO |
SELL
Open market or private sale
|
Direct |
31,540
-9.35%
|
$977,740
$31.06 P/Share
|
|
Mar 20
2025
|
Steven George Hughes Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
9,578
-11.62%
|
$296,918
$31.06 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 651K shares |
|---|---|
| Exercise of conversion of derivative security | 513K shares |
| Bona fide gift | 22.5K shares |
| Open market or private sale | 811K shares |
|---|---|
| Bona fide gift | 22.5K shares |